Showing results (41-50 of 130) with videos related to
Sort By:
Pageof 13
Oncotargets and Therapy|August 30, 2021
Clinical Utility of Fedratinib in MyelofibrosisJulian A Waksal, Douglas Tremblay, John MascarenhasJournal of Blood Medicine|September 16, 2024
Management of Advanced Systemic Mastocytosis: Clinical ChallengesDouglas Tremblay, Nicole E Wagner, John MascarenhasThe Oncologist|October 6, 2025
Antibody drugs conjugates in small-cell lung cancer: present-day status and promisesArjun Syal, May-Lucie Meyer, Kenneth Angelino, et al.The Oncologist|October 6, 2025
Antibody drugs conjugates in non-small cell lung cancer: current status and challengesArjun Syal, May-Lucie Meyer, Kenneth Angelino, et al.Leukemia & Lymphoma|March 9, 2019
Predictors of early hemorrhage in acute promyelocytic leukemiaLeonard Naymagon, Erin Moshier, Douglas Tremblay, et al.JAMA|November 18, 2024
Diagnosis and Treatment of Polycythemia Vera: A ReviewDouglas Tremblay, Marina Kremyanskaya, John Mascarenhas, et al.Leukemia|April 19, 2025
Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a practical guide to diagnosis and managementDouglas Tremblay, Robert P Hasserjian, Raajit K RampalQuality Management in Health Care|May 28, 2021
A Rapid Guidance Process for the Development of an Anticoagulation Protocol in the COVID-19 PandemicDouglas Tremblay, Andrew S Dunn, William K OhClinical Lymphoma, Myeloma & Leukemia|September 19, 2015
Systemic Mastocytosis: Clinical Update and Future DirectionsDouglas Tremblay, Nicole Carreau, Marina Kremyanskaya, et al.European Journal of Haematology|May 1, 2020
Soluble interleukin-2 receptor (sIL-2r) level is a limited test for the diagnosis of adult secondary hemophagocytic lymphohistiocytosisLeonard Naymagon, Douglas Tremblay, Kevin Troy, et al.Pageof 13